Nikola Trbovic, PhD, has over 10 years’ experience in the life sciences industry spanning research strategy, company building, clinical portfolio management, and corporate venture capital, across therapeutic areas and modalities.
Dr. Trbovic is a Partner in the Biotech team at SV Health Investors and is responsible for investments in Nimbus, Sitryx, TRexBio, and Caraway Therapeutics. Prior to SV, he was a Partner at Pfizer Ventures, where he was responsible for investments in emerging companies developing transformative medicines aligned with Pfizer’s strategic vision. Prior to his role with Pfizer Ventures, Dr. Trbovic held responsibilities for R&D strategy and early clinical portfolio management within Pfizer’s R&D organization. Dr. Trbovic joined Pfizer from McKinsey & Co., where he advised leading pharmaceutical, biotech, and healthcare companies on a range of strategic and commercial topics as a senior member of the Pharmaceuticals Practice.
Dr. Trbovic holds a Diplom in Biochemistry from Goethe University Frankfurt and received his PhD in Biochemistry and Molecular Biophysics from Columbia University.